Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446998 · ClinicalTrials.gov registry record · Phase 2
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
A Phase 2 study, sponsored by Veru.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07446998 is a Phase 2 study that is actively recruiting participants, run by Veru. The registered enrollment target is 200 participants.
The verdict
NCT07446998, a Phase 2 study, is actively recruiting participants, sponsored by Veru.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the effect of enobosarm on total body weight
Interventions
- DRUG Enobosarm
- DRUG Semaglutide (Wegovy) weekly injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07446998
The ClinicalTrials.gov registry entry for NCT07446998 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enobosarm is the first listed.
NCT07446998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07446998 about?
NCT07446998 is a clinical study titled "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss". The primary objective of this study is to assess the effect of enobosarm on total body weight
What is the current status of trial NCT07446998?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-03-26. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07446998?
The interventions under investigation include: Enobosarm (DRUG), Semaglutide (Wegovy) weekly injection (DRUG).
Who is sponsoring clinical trial NCT07446998?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.